Published in Women's Health Weekly, November 13th, 2003
The company reported a consolidated loss of $843,000, or $0.07 per share, for the current quarter compared to a loss of $1,046,000, or $0.08 per share, for the first fiscal quarter of a year ago.
The loss was in line with previous guidance and continues to reflect the impact of reduced gynecologic sales, unused hyaluronan-manufacturing capacity charges, and consulting and professional fee expenses associated with the market withdrawal of Gynecare...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.